創美藥業(02289.HK)將於2020年7月10日派末期息 每股0.218539港元
格隆匯5月25日丨創美藥業(02289.HK)公佈,公司將向於2020年6月3日(星期三)名列公司股東名冊的股東派付截至2019年12月31日止年度的末期股息每股人民幣0.20元(含税),其中內資股股息金額為人民幣1,600萬元(含税),H股股息金額為人民幣560萬元(含税)。就分派2019年末期股息而言,內資股股息將以人民幣派付,而H股股息將以港元,應付每股H股2019年末期股息為0.218539港元(含税)。公司已委任香港中央證券信託有限公司為香港收款代理,代H股持有人收取公司宣派的2019年末期股息。2019年末期股息將由收款代理支付,而公司H股股份過户登記處香港中央證券登記有限公司將與2020年7月10日或之前,以平郵方式向有權收取2019年末期股息的H股持有人寄出股息單,郵誤風險由彼等自行承擔。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.